Poolbeg-led consortium awarded €2.3m in non-dilutive funding to progress Oral Vaccine PlatformTransformative oral vaccine platform funded by the Disruptive Technologies Innovation FundLONDON, UK / ACCESSWIRE
First time AI has been used to identify disease targets in RSVLONDON, UK / ACCESSWIRE / November 8, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical stage infectious